Product of C-reactive protein and fasting C-peptide indicates cardiovascular risk in type 2 diabetes: A real-world study

Figure 3 Comparison of C-reactive protein, fasting C-peptide, and C-reactive protein-fasting C-peptide product levels according to the cardiovascular, cerebrovascular, and cardio-cerebrovascular event status, and their trends across product quartiles. A-C: Serum C-reactive protein (CRP; A), fasting C-peptide (FCP; B) and CRP-FCP (C) levels in patients with and without cardiovascular events (CVEs), cerebrovascular events (CBVEs), and cardio-CBVEs (CCBVEs); D: Prevalence of CVEs, CBVEs, and CCBVEs stratified by CRP-FCP product quartiles; E and F: Serum CRP (E) and FCP (F) levels stratified by CRP-FCP product quartiles; G: Correlation between serum CRP and FCP levels. CRP: C-reactive protein; FCP: Fasting C-peptide; CVEs: Cardiovascular events; CBVEs: Cerebrovascular events; CCBVEs: Cardio-cerebrovascular events.